Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
0 0  (0%)
TradingVolume：0
01-27
2026
DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE
Publisher：
01-27
2026
DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY ...
Publisher：
01-08
2026
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR CLASS 1 INNOVATIVE DRUG RUOXINLIN FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER ACCEPTED IN CHINA
Publisher：
01-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Publisher：
12-31
2025
Terms of Reference for Nomination Committee of the board of directors of the Company
Publisher：
12-31
2025
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Publisher：
12-31
2025
APPOINTMENT OF NOMINATION COMMITTEE MEMBER
Publisher：
12-28
2025
DISCLOSEABLE TRANSACTIONS TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS
Publisher：
12-24
2025
VOLUNTARY ANNOUNCEMENT THE GRANT OF EXCLUSIVE COMMERCIALIZATION RIGHTS TO NHWA FOR THREE LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN THE CHINESE MAINLAND
Publisher：
12-12
2025
DISCLOSEABLE TRANSACTION COMPLETION OF THE ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume：0
0
0  (0%)
Announcement & Circular
01-27
2026
DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE
01-27
2026
DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER
01-08
2026
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR CLASS 1 INNOVATIVE DRUG RUOXINLIN FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER ACCEPTED IN CHINA
01-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
12-31
2025
Terms of Reference for Nomination Committee of the board of directors of the Company
12-31
2025
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
12-31
2025
APPOINTMENT OF NOMINATION COMMITTEE MEMBER
12-28
2025
DISCLOSEABLE TRANSACTIONS TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS
12-24
2025
VOLUNTARY ANNOUNCEMENT THE GRANT OF EXCLUSIVE COMMERCIALIZATION RIGHTS TO NHWA FOR THREE LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN THE CHINESE MAINLAND
12-12
2025
DISCLOSEABLE TRANSACTION COMPLETION OF THE ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY
First
1
2
3
4
5
Last